Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTX311
- Development stage
- Preclinical
- Lead developer
- Dome Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
DTX311 is a **nanomedicine program from Dome Therapeutics** based on next-generation polymeric nanoparticles designed for brain-targeted delivery. For the Alzheimer's disease program, Dome's public materials identify the asset as a preclinical or discovery-stage candidate, but do not disclose the specific therapeutic payload, molecular target, route of administration, or detailed mechanism beyond a nanoparticle-based approach intended to reach brain cell populations. The platform is described as originating from Johns Hopkins University research and is part of a broader DTX311 franchise spanning central nervous system indications including glioblastoma, medulloblastoma, and Alzheimer's disease.
Beyond the preview
Go deeper on DTX311.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTX311.